Stock listing

Frankfurt:E2Z Almirall SA Aktie

German listing (Frankfurt) of Almirall SA · home listing BME:ALM

Follow Almirall SA into a list and get an email when it puts out news.

Share price · FWB:E2Z

€10.58 EUR +0.20 (+1.9%)

Close on Oct 30, 2026

Day range
€10.46 – €10.58 EUROct 30, 2026
Market cap
€2.30B EURAt the close on Oct 30, 2026 · price × 217.6M shares outstanding
Almirall SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
BME:ALM · Home€10.60 EUR+0.08 (+0.8%)68,697€10.56€10.68€10.56€10.52Close on Oct 30, 2026
OTC:LBTSF$15.35 USD0.00 (0.0%)—$15.35$15.35$15.35$15.35Close on Oct 27, 2026
Frankfurt:E2Z€10.58 EUR+0.20 (+1.9%)—€10.46€10.58€10.46€10.38Close on Oct 30, 2026
Ticker
Frankfurt:E2Z
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Almirall (Madrid:ALM) Q2 2026 Earnings Call

    Fri, Jul 24, 2026 · 4:00 AM ET

    Watch Transcript

  • Almirall (Madrid:ALM) Q1 2026 Earnings Call

    Mon, May 11, 2026 · 4:00 AM ET

    Watch Transcript

  • Almirall (Madrid:ALM) Q4 2025 Earnings Call

    Mon, Feb 23, 2026 · 4:00 AM ET

    Watch Transcript

Latest news

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

Oct 1, 2026

Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Sep 30, 2026

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

Aug 10, 2026

Almirall H1 2026 Results

Jul 24, 2026

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Jul 20, 2026

Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business

May 11, 2026

Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology

Apr 13, 2026

Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology

Mar 30, 2026

Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis

Mar 27, 2026

AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne

Mar 26, 2026

All Almirall SA news

Decks

Almirall SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 35 in all · newest Oct 1, 2026 · oldest 2024
Calls
14 calls with a replay · 14 with a transcript · latest Jul 24, 2026
Decks
21 decks · latest Jul 24, 2026

Where Almirall SA is listed

ListingExchangeCountryCurrency
BME:ALM · Home listingMadridSpainEUR
gettex:E2ZgettexGermanyEUR
LS Exchange:A0MU8YLS ExchangeGermanyEUR
OTC:ALMRYOTCUnited StatesUSD
Lang & Schwarz:A0MU8YLang & SchwarzGermanyEUR
Aquis:ALMEAquisUnited KingdomEUR
LSIN:0O9BLSINUnited KingdomEUR
OTC:LBTSFOTCUnited StatesUSD
Aquis:ALMEAquisUnited KingdomEUR
Tradegate:E2ZTradegateGermanyEUR
Frankfurt:E2Z · This pageFrankfurtGermanyEUR
Frankfurt:E2Z0FrankfurtGermanyEUR
VIE:ALMViennaAustriaEUR
Dusseldorf:E2ZDusseldorfGermanyEUR
Hamburg:E2ZHamburgGermanyEUR
Munich:E2ZMunichGermanyEUR
Stuttgart:E2ZStuttgartGermanyEUR
Turquoise:ALMETurquoiseUnited KingdomEUR

Log in to ask 6ix AI your own questions about Almirall SA.